Free Trial

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

Verrica Pharmaceuticals logo
$5.51 -0.04 (-0.74%)
As of 02:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)

Key Stats

Today's Range
$5.43
$5.75
50-Day Range
$5.23
$8.73
52-Week Range
$3.82
$25.20
Volume
26,327 shs
Average Volume
42,899 shs
Market Capitalization
$52.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.00
Consensus Rating
Hold

Company Overview

Verrica Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

VRCA MarketRank™: 

Verrica Pharmaceuticals scored higher than 92% of companies evaluated by MarketBeat, and ranked 102nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verrica Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Verrica Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.46) to ($0.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verrica Pharmaceuticals is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verrica Pharmaceuticals is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Verrica Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    2.99% of the float of Verrica Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verrica Pharmaceuticals has recently decreased by 32.28%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Verrica Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Verrica Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.99% of the float of Verrica Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verrica Pharmaceuticals has recently decreased by 32.28%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Verrica Pharmaceuticals has a news sentiment score of 1.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    54.00% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verrica Pharmaceuticals' insider trading history.
Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRCA Stock News Headlines

Verrica Posts Profit in Fiscal Q2
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
See More Headlines

VRCA Stock Analysis - Frequently Asked Questions

Verrica Pharmaceuticals' stock was trading at $7.00 at the beginning of 2025. Since then, VRCA stock has decreased by 21.3% and is now trading at $5.5090.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings results on Tuesday, August, 12th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.70) by $0.72. The business had revenue of $12.70 million for the quarter, compared to analyst estimates of $4.37 million.
Read the conference call transcript
.

Verrica Pharmaceuticals's stock reverse split on the morning of Friday, July 25th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Verrica Pharmaceuticals' top institutional shareholders include Armistice Capital LLC (96.01%), Sovran Advisors LLC (0.81%), Geode Capital Management LLC (6.99%) and Y Intercept Hong Kong Ltd (2.02%). Insiders that own company stock include Paul B Manning, Perceptive Advisors Llc, Ted White, Christopher G Hayes and Joe Bonaccorso.
View institutional ownership trends
.

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Marathon Oil (MRO), Centrus Energy (LEU) and Clean Energy Fuels (CLNE).

Company Calendar

Last Earnings
8/12/2025
Today
8/29/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VRCA
CIK
1660334
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$120.00
Low Price Target
$20.00
Potential Upside/Downside
+1,341.4%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($8.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.58 million
Net Margins
N/A
Pretax Margin
-330.52%
Return on Equity
N/A
Return on Assets
-115.48%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.26
Quick Ratio
1.17

Sales & Book Value

Annual Sales
$14.70 million
Price / Sales
3.57
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.85) per share
Price / Book
-3.00

Miscellaneous

Outstanding Shares
9,446,000
Free Float
4,345,000
Market Cap
$52.43 million
Optionable
Optionable
Beta
1.92

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:VRCA) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners